Intra Cellular Therapies reported $70.63M in Current Liabilities for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Acadia Pharmaceuticals ACAD:US $ 117.68M 1.92M
ALKERMES ALKS:US $ 438.52M 23.84M
Aptinyx Inc APTX:US $ 5.68M 945K
Biogen BIIB:US $ 5018M 1071.4M
Bristol Myers Squibb BMY:US $ 20915M 1906M
Cytokinetics CYTK:US $ 66.84M 0M
Esperion Therapeutics ESPR:US $ 82.28M 3.19M
Gilead Sciences GILD:US $ 9220M 662M
Halozyme Therapeutics HALO:US $ 199.51M 87.82M
Intra Cellular Therapies ITCI:US $ 70.63M 11.56M
JAZZ PHA JAZZ:US $ 705.44M 31.97M
Marinus Pharmaceuticals MRNS:US $ 23.11M 3.57M
Minerva Neurosciences NERV:US $ 3.41M 0.16M
Nektar Therapeutics NKTR:US $ 104.98M 0.3M
Neurocrine Biosciences NBIX:US $ 285.7M 32.2M
Novartis NVS:US $ 27646M 2161M
Prothena PRTA:US 40.11M 3.61M
Redhill Biopharma RDHL:US $ 73.9M 7.57M
Supernus Pharmaceuticals SUPN:US $ 735.54M 450.98M
United Therapeutics UTHR:US $ 331.5M 38.9M
Vanda Pharmaceuticals VNDA:US $ 88.4M 2.34M